@waynesworld
"It could be with a pharma or biotech who either wants to move into DMD or orphan disease indications more generally speaking or sees the opportunity for ATL1102 as a novel anti-inflammatory drug in multiple disease indications including MS and long Covid."
Wayno,
If the area of interest for potential partner is both DMD and the broader anti-inflammatory market across multiple diseases...then it would be a pretty large Pharma who has the resources and $$$ to go broad and big.
In this case, the partnership deal becomes a little more expensive in my opinion, if PER give rights for the full potential to one player.
Interesting times...
PER is full of connections to CSL - there is Moses, Gittleson, McKenzie... not quite in their wheelhouse but never say never.
.
@waynesworld "It could be with a pharma or biotech who either...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 7.9¢ | 7.6¢ | $148.9K | 1.895M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 48919 | 7.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 70000 | 1 |
View Market Depth
| Last trade - 15.59pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.8¢ |
Change
0.000 ( 2.63 %) |
||||
| Open | High | Low | Volume | ||
| 7.7¢ | 7.9¢ | 7.7¢ | 43057 | ||
| Last updated 13.04pm 03/05/2024 ? | |||||
| PER (ASX) Chart |